Unbound MEDLINE

Twice-Daily Cysteamine Bitartrate Therapy for Children with Cystinosis. The Journal of pediatrics [J Pediatr] Journal article

 
TitleTwice-Daily Cysteamine Bitartrate Therapy for Children with Cystinosis.
Author(s)Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA 
InstitutionDepartment of Pediatrics, University of California San Diego, La Jolla, CA (R.D., M.F., J.G., J.S., B.B.) and Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY (F.K.).
SourceJ Pediatr 2009 Sep 21.
AbstractOBJECTIVE: Cystinosis causes renal and other organ failure. Regular 6-hourly cysteamine bitartrate (Cystagon; Mylan, Morgantown, West Virginia) reduces intracellular cystine and the rate of organ deterioration. A formulation of cysteamine requiring less frequent dosing may improve compliance and possibly patient outcome.
METHODS: Enteric-release cysteamine was prepared. For a period of 1 month, patients received their regular cysteamine dose every 6 hours (stage I). The patients then underwent pharmacokinetic and pharmacodynamic studies following washout periods using single-doses of cysteamine and enteric-release cysteamine (stage II). Finally, the patients commenced regular enteric-release cysteamine therapy (stage III). Weekly trough white blood cell (WBC) cystine levels were recorded.
RESULTS: Seven children with cystinosis (mean age, 11.8 years; range, 8-17 years) who received cysteamine and enteric-release cysteamine (mean dose, 45 and 28.8 mg/kg body weight/day, respectively) had mean WBC cystine levels of 0.7+/-0.3 and 0.41+/-0.22 nmol half-cystine/mg protein in study stages I and III, respectively. Study stage II showed that the mean time (T(max)) to reach the maximum plasma cysteamine level (C(max)) was longer for enteric-release cysteamine than for cysteamine (176 minutes vs 60 minutes; P=.001), but the mean C(max) at the same dose was similar. Mean serum gastrin levels were similar after ingestion of cysteamine and enteric-release cysteamine.
CONCLUSIONS: Twelve-hour enteric-release cysteamine, given at approximately 60% of the previous daily dose of cysteamine, was effective in maintaining trough WBC cystine levels within a satisfactory range.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19775699
  
Advertise on this site.